Tetrandrine inhibits glioma stem-like cells by repressing β-catenin expression

Yong Zhang1, Yu-Lin Wen1, Ji-Wei Ma1

  • 1Department of Pathology, Medical School of Jinan University, Guangzhou, Guangdong 510632, P.R. China.

Insights

Tetrandrine (Tet) inhibits self-renewal and migration in glioma stem-like cells (GSLCs) by targeting beta-catenin. This study suggests Tet is a potential therapeutic strategy for glioma treatment, reducing cancer stem cell (CSC) resistance.

Area of Science:

  • Oncology
  • Neuroscience
  • Pharmacology

Background:

  • Cancer stem cells (CSCs) drive glioma relapse and therapeutic resistance.
  • Glioma stem-like cells (GSLCs) exhibit neural stem cell properties, including elevated ALDH1 and beta-catenin expression.
  • Identifying novel therapeutic targets for glioma is crucial.

Purpose of the Study:

  • To investigate the inhibitory effects of tetrandrine (Tet) on GSLC self-renewal and migration.
  • To elucidate the molecular mechanisms underlying Tet's action in GSLCs.
  • To evaluate Tet as a potential therapeutic agent for glioma.

Main Methods:

  • Enrichment of GSLCs from U87 and U251 glioblastoma cell lines using neurosphere culture.
  • Assessment of cell viability (CCK-8), apoptosis (Bax, PARP, Bcl-2), sphere formation, and migration (Transwell assay).
  • Analysis of beta-catenin nuclear translocation and expression via Western blotting and immunofluorescence.

Main Results:

  • Tetrandrine significantly reduced GSLC viability, sphere formation, and migration in a dose-dependent manner.
  • Tet inhibited beta-catenin nuclear translocation and expression, crucial for maintaining GSLC stemness.
  • Tet induced apoptosis in GSLCs, evidenced by altered Bax, PARP, and Bcl-2 levels.

Conclusions:

  • Beta-catenin signaling is vital for maintaining the stem cell characteristics of GSLCs.
  • Tetrandrine effectively inhibits GSLC proliferation, self-renewal, and migration.
  • Inhibition of beta-catenin by Tet represents a promising therapeutic strategy for glioma treatment.